Buying GLP-1 medicines in Canada: Mounjaro, Wegovy and import

Find the Canadian product and its DIN

Look up the brand, active ingredient and presentation in Health Canada's Drug Product Database. You can search by Drug Identification Number, known as a DIN. Before you buy, ask for the DIN of the product the pharmacy will dispense, then match the formulation and strength. A photo of a foreign box proves nothing. Neither does the same ingredient appearing in another Canadian medicine.

The product checks below confirm Canadian authorisations for Mounjaro and Wegovy injection. They also separate an orforglipron submission under review from a granted approval. Each presentation still needs its own DIN, current monograph and supply check. Ask the pharmacy about stock of each strength.

Mounjaro in Canada is authorised for type 2 diabetes

Health Canada first authorised Mounjaro on 24 November 2022 to improve glucose control in adults with type 2 diabetes. A notice dated 23 June 2026 added an indication for patients aged 10 to under 18 with type 2 diabetes, in specified combinations with metformin or basal insulin. Both are diabetes indications. The UK Mounjaro weight-management label does not carry over into a Canadian prescription.

The Drug Product Database lists each presentation separately. The Mounjaro KwikPen entry linked below, DIN 02551969, is marked Marketed, with a status date of 10 December 2024. A separate single-dose pen record is marked Approved. Read authorisation and marketed status pack by pack. Neither status tells you a particular pharmacy has stock. Ask which Canadian presentation your prescription covers and get its own instructions.

Wegovy injection in Canada is approved for weight management

Health Canada authorised Wegovy injection on 23 November 2021 for chronic weight management alongside diet and activity. The adult criteria in that decision were a BMI of at least 30, or at least 27 with a weight-related condition. A June 2023 decision extended the indication to qualifying adolescents aged 12 to under 18 with obesity, body weight above 60 kg and an inadequate response to diet and activity alone.

The current database also holds marketed multidose pen records, including the linked 0.5 mg-dose presentation. A January 2026 Health Canada bulletin reports a conditional authorisation for non-cirrhotic MASH in adults with moderate-to-advanced liver fibrosis. Each indication has its own clinical requirements. Ask the clinician which one applies and read the current Canadian monograph. The original adult obesity approval is only part of today's label.

Wegovy tablets have no confirmed Canadian authorisation

The Health Canada records cited below cover Wegovy injection only. They show no authorisation for Wegovy tablets. A Rybelsus tablet record, an oral semaglutide clinical trial or a US Wegovy pill announcement is no proof of Canadian approval. Before you accept an offer, ask for the exact Canadian DIN and monograph, or a clear explanation of any exceptional access pathway. An unconfirmed authorisation does not mean all personal possession is banned.

Foundayo and orforglipron in Canada have no confirmed approval

Health Canada's submissions-under-review list records orforglipron calcium from Eli Lilly Canada, with a submission month of January 2026. A review entry is no Notice of Compliance, no Canadian Foundayo brand authorisation and no retail launch. The dated entry also cannot confirm the application is still pending today. Check the current Drug Product Database and latest decisions before you buy. A clinical-trial listing describes research access, separate from ordinary pharmacy supply. The records cited below confirm no Canadian retail authorisation for Foundayo.

Get care and dispensing in your own province

Ask the service where the prescriber is licensed and which pharmacy will dispense. Check both with the relevant provincial or territorial professional regulator. A website may market across Canada while using different clinical or dispensing arrangements in each province. Make sure the service covers your actual location and you know how to reach a pharmacist if something goes wrong.

Bring a short treatment history to the assessment: why treatment is being considered, medicines already used, the current dose if any, the date of the last dose, past side effects and relevant health conditions. A local clinician may need more information before continuing a prescription started overseas. Transferring treatment involves more than asking a pharmacy to swap one box for another.

Residents and visitors face different import rules

Health Canada's personal-use guidance treats Canadian residents and visitors differently. Prescription medicines carry specific import restrictions. The familiar 90-day personal-use wording gives Canadian residents no unrestricted right to order prescription drugs from foreign websites. The guidance covers limited situations, so read the part for your status and for the way the medicine will arrive.

A resident of another country visiting Canada may be able to bring a personal prescription supply under the visitor rules. Those rules do not turn the same overseas supplier into an authorised source for routine mail orders by residents. Before you travel or arrange a shipment, confirm packaging, documents and quantity against the official guidance. Keep evidence the medicine is for your own continuing treatment.

Find out exactly what your drug plan covers

Ask your public or private drug plan about the exact product, the indication and your own eligibility. Health Canada approval and plan reimbursement are separate decisions. Check whether prior authorisation, earlier treatment records, a preferred pharmacy or renewal assessments apply. A general statement about diabetes medicines tells you nothing reliable about an obesity prescription.

If you may pay yourself, ask for an itemised private quote. The quote should show the medicine quantity, dispensing charge, delivery fee and the cost of clinical follow-up. Ask how long the quote stays valid and what happens if your strength is out of stock. Budget for the ongoing plan agreed with your prescriber. A low introductory price is a poor guide. Do not pay for more treatment than your clinician has agreed.

Check a Canadian online pharmacy yourself

Health Canada publishes advice on choosing a safe online pharmacy. Start from an official regulator page you find yourself, never from a badge on the seller's site. Match the pharmacy name, address and contact details. Ask for direct access to a pharmacist, a clear prescription process and where the medicine will be supplied from. A Canadian domain name or maple-leaf logo answers none of these.

If a product is sold as identical to a named brand, ask for its exact product name and regulatory status. A compounded preparation, research product or imported presentation may lack the approval, device instructions or evidence behind the branded medicine. If the seller cannot say what will arrive and who is professionally accountable, do not order.

Plan travel and delivery separately

A Canadian prescription gives you no permission to take the medicine into the next country. Check each destination's rules, including transit stops where you enter the country. Keep the original packaging and a copy of the prescription. For a long stay elsewhere, arrange continuing care before you leave and ask your clinician what to do about delayed travel or a missed dose.

For deliveries within Canada, ask the pharmacy about the transport requirements of your exact product. The pharmacy should give you a way to report a late, damaged or temperature-exposed parcel. Record the problem and ask the pharmacist to assess the product before you use it. Current stock, insurance benefits and the import status of each medicine depend on the product and your circumstances, so check them each time.